Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: A randomized, head-to-head clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 8, 2013, Pages 3206-3212

  Anastasilakis, Athanasios D ^a   Polyzos, Stergios A ^b   Gkiomisi, Athina ^a   Bisbinas, Ilias ^a   Gerou, Spyridon ^c   Makras, Polyzois ^d  

^a 424 General Army Hospital   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Laboratories Analysis   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; DICKKOPF 1 PROTEIN; OSTEOPROTEGERIN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; PROTEIN PRECURSOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCLEROSTIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MASS; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG INFUSION; DRUG MECHANISM; DRUG POTENCY; FEMALE; FOLLOW UP; GREECE; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEINS; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; GENETIC MARKERS; HUMANS; IMIDAZOLES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; OSTEOPROTEGERIN; PEPTIDE FRAGMENTS; PEPTIDES; POSTMENOPAUSE; PROCOLLAGEN; RANK LIGAND;

EID: 84881495777     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1402     Document Type: Article

References (21)

1. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617-627.
2. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.NEngl J Med. 2007; 356:1809-1822.
3. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
4. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733-759.
5. Lacey DL, Timms E, Tan H, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-176.
6. Nakashima T, HayashiM, Fukunaga T, et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011;17:1231-1234.
7. Anastasilakis AD, Polyzos SA, Toulis KA. Role of wingless tail signaling pathway in osteoporosis: an update of current knowledge. Curr Opin Endocrinol Diabetes Obes. 2011;18:383-388.
8. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-19887.
9. Mao B, Wu W, Davidson G, et al. Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling. Nature. 2002;417: 664-667.
10. Li J, Sarosi I, Cattley RC, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006;39:754-766.
11. Drake MT, Srinivasan B, Mödder U, et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab. 2010;95:5056-5062.
12. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171-1176.
13. Voskaridou E, Christoulas D, Xirakia C, et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica. 2009;94:725-728.
14. Polyzos SA, Anastasilakis AD, Efstathiadou Z, et al. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone. Horm Metab Res. 2009; 41:846-850.
15. Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone. 2012;50:739-742.
16. Chung YE, Lee SH, Lee SY, et al. Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int. 2012;23:1235-1243.
17. Memon AR, Butler JS, O'Riordan MV, Guerin E, Dimitrov BD, Harty JA. Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment. J Clin Densitom. 2013;16:118-124.
18. Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB. Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading. Bone. 2007;40:1172-1177.
19. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008;23:1712-1721.
20. Gatti D, Viapiana O, Fracassi E, et al. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res. 2012;27:2259-2263.
21. Anastasilakis AD, Goulis DG, Polyzos SA, et al. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. Horm Metab Res. 2008;40:281-285.